Difference between revisions of "Talk:Ancillary testing in prostate cancer"

Talk:Ancillary testing in prostate cancer (view source)

1 byte removed , 15:20, 1 November 2022

no edit summary

48,470

edits

Revision as of 15:17, 1 November 2022 (view source) Michael (talk \| contribs) (Created page with "MSI testing - in BRCA1/2: {{cite journal \|vauthors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R...")		Latest revision as of 15:20, 1 November 2022 (view source) Michael (talk \| contribs)
Line 1:		Line 1:
	MSI testing - in BRCA1/2: {{cite journal \|~~vauthors~~=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O \|title=Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA \|journal=J Immunother Cancer \|volume=8 \|issue=2 \|pages= \|date=August 2020 \|pmid= \|pmc=7422632 \|doi=10.1136/jitc-2020-001065 \|url=}}		MSI testing - in BRCA1/2: {{cite journal \|authors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O \|title=Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA \|journal=J Immunother Cancer \|volume=8 \|issue=2 \|pages= \|date=August 2020 \|pmid= \|pmc=7422632 \|doi=10.1136/jitc-2020-001065 \|url=}}